Urinary Free Cortisol-Based Thresholds for Differentiating ACTH-Dependent Cushing's: A Spanish Validation Study.
retrospective_cohort · Level III
Where this comes from
- Record sourced from PubMed, PMID 42063386.
- Also identified by DOI 10.1210/clinem/dgag187.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Differentiating ectopic ACTH secretion (EAS) from Cushing's disease (CD) remains one of the most challenging steps in the diagnostic workup of ACTH-dependent Cushing's syndrome (CS). Urinary free cortisol (UFC) expressed as times above the upper limit of normal (ULN) has been proposed as a simple, noninvasive discriminator, but external validation in independent populations is lacking. To validate the diagnostic performance of UFC×ULN for distinguishing EAS from CD and to explore complementary biochemical markers, including late-night salivary cortisol (LNSC×ULN) and hypokalemia. Multicenter retrospective study from the Spanish Cushing Registry including 269 patients with ACTH-dependent Cushing's syndrome (208 CD, 61 EAS) diagnosed and managed in tertiary referral centers. Diagnostic accuracy of UFC×ULN and LNSC×ULN for discriminating EAS from CD, expressed as area under the ROC curve (AUC), sensitivity, specificity, and predictive value. EAS patients were older (median 59.0 vs 44.9 years; P<0.001) and showed higher UFC×ULN (16.6 vs 3.6; P<0.001) and LNSC×ULN (9.3 vs 1.5; P<0.001). UFC×ULN and LNSC×ULN achieved excellent discriminative performance (AUC 0.90 and 0.92). No EAS occurred with UFC×ULN < 3×ULN, while 40.5% of patients with UFC ≥ 10×ULN had EAS. The combination of severe hypercortisolism (UFC ≥ 10×ULN and LNSC ≥ 9×ULN) plus hypokalemia identified 75% of EAS with 98% specificity. UFC×ULN thresholds reliably stratify the probability of EAS versus CD. Severe hypercortisolism and hypokalemia strongly predict EAS, supporting a pragmatic diagnostic approach that prioritizes whole-body imaging in high-risk patients and pituitary-centered evaluation in mild cases.